The NT-ProBNP Test in Subjects with End-Stage Renal Disease on Hemodialysis Presenting with Acute Dyspnea : Is Knowing Worth the Cost?

Abstract EN

Background.

The NT-ProBNP/BNP test has been validated as a marker for determining the etiology of acute dyspnea.

In the setting of end-stage renal disease on hemodialysis (ESRD on HD), the utility of the NT-ProBNP/BNP test has not been validated.

This study examines the clinical utility of the NT-ProBNP test in the setting of ESRD on HD patients presenting with acute dyspnea.

Methods.

A retrospective case series of 250 subjects were admitted to Cooper University Hospital, 07/2010-03/2011, with ESRD and HD presenting with dyspnea.

The incidences of echocardiography, cardiology consultation, and NT-ProBNP elevated and normal were examined.

Correlation coefficients were calculated for NT-ProBNP with age (years), estimated dry weight (kg), amount of fluid removed (L), and ejection fraction (EF in %) among other echocardiography parameters.

Results.

Of the total sample 235 patients had NT-ProBNP levels performed.

Cardiology consults were placed in 68.8% and 58% who underwent echocardiography.

Of those for whom an echocardiography was performed estimated mean EFs of 54.6%, 50.8%, and 61.7% were observed among the NT-ProBNP elevated group, normal group, and no NT-ProBNP group, respectively.

No differences were detected in all other echocardiography measurements.

No correlation was observed between NT-ProBNP and age (r=0.05), baseline EDW (r=−0.09), amount of fluid removed (r=0.07), or EF (r=0.02).

Conclusion.

In the setting of ESRD on HD, the NT-ProBNP test has no clinical utility in determining the etiology of acute dyspnea.

This can be demonstrated through echocardiographic and therapeutic parameters measured in this study.